Please assess the completion status of the following clinical trial:

Trial Title: Stress and Inflammation in Late-Life Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80, male or female, any race;~2. Absence of clinical dementia~3. English speaking~4. Blood pressure not exceeding 150/90 mmHg, treated or untreated~5. Weight greater than 110 lbs~6. Normal result on liver-function test~7. No history of ulcer disease or GI bleeding~8. No renal insufficiency~Additional Inclusion Criteria for Depressed Participants:~1. DSM-IV criteria for Major Depressive Disorder~2. HAM-D greater than 18~Exclusion Criteria:~1. Known history of relevant severe drug allergy or hypersensitivity (e.g. to Citalopram or Escitalopram, and/or to celecoxib, aspirin, or other NSAIDs only for Phase 2; known demonstration of allergic-type reactions to sulfonamides);~2. Does not speak English;~3. Cannot give informed consent;~4. MRI contraindications (e.g., foreign metallic implants, pacemaker);~5. Known primary neurological disorders, such as Parkinson's disease, Alzheimer's disease, traumatic brain injury, cognitive impairment or dementia,~6. Known severe inflammatory disease such as systemic lupus erythematosis, known autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis; Screen + for RF, ANA, HIV, Hepatitis B or C.~7. Clinical Dementia Rating Scale score greater than 0;~8. Diagnosis of a chronic psychiatric illness other than MDD at the discretion of the study doctor;~9. Significant handicaps (e.g. uncorrected hearing or visual impairment, mental retardation) that would interfere with testing;~10. Bleeding diathesis;~11. Severe Medical problem, which in the opinion of the investigator would pose a safety risk to the subject;~12. Clinically significant cardiovascular disease that will be assessed on a case-by-case basis. Clinically significant cardiovascular disease usually includes one or more of the following: cardiac surgery or myocardial infarction within the last 4 weeks; unstable angina; acute decompensated congestive heart failure or class IV heart failure; current significant cardiac arrhythmia or conduction disturbance, particularly those resulting in ventricular fibrillation, or causing syncope or near syncope; uncontrolled high blood pressure; QTc greater than 450msec (by history for subjects with cardiac disease); documented prior stroke;~13. Clinically significant abnormalities on EKG. Primary AV block or Right bundle branch block are not necessarily exclusionary;~14. Current diagnosis of cancer~15. Current diagnosis of HIV, active Hepatitis B and/or Hepatitis C~16. Use of an Investigational medicine within the past 30 days;~17. Use of Coumadin, Warfarin within the past 2 months;~18. Current treatment with psychotropic drugs or drugs that affect the CNS such as beta-blockers, mood stabilizers, antipsychotics, steroids or non-steroidal anti-inflammatory medications or other antidepressants. No subjects will be included in the study unless they have been off all psychotropics for at least 3 weeks, except in the case of fluoxetine, where 5 weeks off treatment will be required;~19. Current alcohol or substance abuse disorder, schizophrenia or other psychotic disorder, bipolar disorder, or current OCD;~20. Abnormal liver-function test~21. History of ulcer disease, Chron's disease, GI bleeding or anemia~22. Weight less than 110 lbs~23. Renal insufficiency~24. Any other factor that in the investigator's judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from this facility);~Additional Exclusion Criteria for Depressed Subjects:~1) Active suicidality or current suicidal risk as determined by the investigator

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): This arm is for participants who are not depressed.
- Experimental - treatment (Type: EXPERIMENTAL): Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).